Evidence map›Paper›PMID 16077030›Full record

ArticleNucleic acids research2005

Anti-HIV-1 activity of anti-TAR polyamide nucleic acid conjugated with various membrane transducing peptides.

Snehlata Tripathi, Binay Chaubey, Sabyasachi Ganguly, Dylan Harris, Ralph A Casale, Virendra N Pandey

Abstract read
In one paragraph

Article in Nucleic acids research, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Discoveries and developments of CXCR4-targeted HIV-1 entry inhibitors.Experimental biology and medicine (Maywood, N.J.) · 2020
    Review
  5. Review
  6. Article
  7. Article
  8. Tailoring silver nanodots for intracellular staining.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2011
    Article
  9. Cell-Penetrating Peptides for Antiviral Drug Development.Pharmaceuticals (Basel, Switzerland) · 2010
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Recent developments in peptide-based nucleic acid delivery.International journal of molecular sciences · 2008
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Snehlata TripathiDepartment of Biochemistry and Molecular Biology, UMDNJ-New Jersey Medical School 185 South Orange Avenue, Newark, NJ 07103, USA.
Binay Chaubey
Sabyasachi Ganguly
Dylan Harris
Ralph A Casale
Virendra N Pandey

Funding

GENOME TARGETED INHIBITORS OF RETROVIRUSESR01AI042520 · NIAID · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI PANDEY, VIRENDRA NATH · 1999 to 2007
$2.2M
Genome Targeted Inhibitors of RetrovirusesR21AI042520 · NIAID · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI PANDEY, VIRENDRA NATH · 2002 to 2002
$272k
NIAID NIH HHS AI42520NIAID NIH HHS R01 AI042520NIAID NIH HHS R21 AI042520
6 · The paper itself

Abstract

The transactivator responsive region (TAR) present in the 5'-NTR of the HIV-1 genome represents a potential target for antiretroviral intervention and a model system for the development of specific inhibitors of RNA-protein interaction. Earlier, we have shown that an anti-TAR polyamide nucleotide analog (PNA(TAR)) conjugated to a membrane transducing (MTD) peptide, transportan, is efficiently taken up by the cells and displays potent antiviral and virucidal activity [B. Chaubey, S. Tripathi, S. Ganguly, D. Harris, R. A. Casale and V. N. Pandey (2005) Virology, 331, 418-428]. In the present communication, we have conjugated five different MTD peptides, penetratin, tat peptide, transportan-27, and two of its truncated derivatives, transportan-21 and transportan-22, to a 16mer PNA targeted to the TAR region of the HIV-1 genome. The individual conjugates were examined for their uptake efficiency as judged by FACScan analysis, uptake kinetics using radiolabeled conjugate, virucidal activity and antiviral efficacy assessed by inhibition of HIV-1 infection/replication. While FACScan analysis revealed concentration-dependent cellular uptake of all the PNA(TAR)-peptide conjugates where uptake of the PNA(TAR)-penetratin conjugate was most efficient as >90% MTD was observed within 1 min at a concentration of 200 nM. The conjugates with penetratin, transportan-21 and tat-peptides were most effective as an anti-HIV virucidal agents with IC50 values in the range of 28-37 nM while IC50 for inhibition of HIV-1 replication was lowest with PNA(TAR)-transportan-27 (0.4 microM) followed by PNA(TAR)-tat (0.72 microM) and PNA(TAR)-penetratin (0.8 microM). These results indicate that anti-HIV-1 PNA conjugated with MTD peptides are not only inhibitory to HIV-1 replication in vitro but are also potent virucidal agents which render HIV-1 virions non-infectious upon brief exposure.

Indexed as

Anti-HIV AgentsAntisense Elements (Genetics)Biological TransportCell MembraneCells, CulturedDNA, ViralGene Products, tatHIV-1HIV Long Terminal RepeatHomeodomain ProteinsKineticsNucleic AcidsNucleotidesPeptide FragmentsPeptide Nucleic AcidsPeptidesAnti-HIV AgentsAntisense Elements (Genetics)DNA, ViralGene Products, tatHomeodomain ProteinsNucleic AcidsNucleotidespenetratin (43-58), humanPeptide FragmentsPeptide Nucleic AcidsPeptidesRecombinant Fusion Proteinstat Gene Products, Human Immunodeficiency Virustat peptide (48-60), Human immunodeficiency virus 1

Identifiers

PMID16077030
PMCPMC1182329

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.